Axsome Therapeutics (AXSM) Misses Q1 EPS by 22c

Axsome Therapeutics (NASDAQ: AXSM) reported Q1 EPS of ($1.44), $0.22 worse than the analyst estimate of ($1.22). Revenue for the quarter came in at $75 million versus the consensus estimate of $74 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• InspireMD (NSPR) Tops Q2 EPS by 1c
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22